CEDARS-SINAI added a treatment center offering radiation oncology therapies less than a mile from the hospital campus. The center will be a collaboration with Integrated Oncology Network, LLC. The 8,500-square-foot facility, at 8929 Wilshire Blvd. in Beverly Hills, will be fully integrated into the Cedars-Sinai medical record system making available lab tests, X-rays and reports....
On Aug. 26, FDA approved the RAS inhibitor, daraxonrasib, sponsored by Revolution Medicines Inc. and also known as Rasonque, for patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy.
